Benzinga's M&A Chatter for Thursday May 1, 2014

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday May 1, 2014: Report AT&T in Talks to Acquire DirecTV The Rumor:
AT&T T is said to have approached DirecTV DTV regarding a potential acquisition, according to a report from the Wall Street Journal. The deal could be worth $40 billion, according to sources. Spokespersons for both companies declined comment to Benzinga on the report. DirecTV closed Thursday at $80.76, a gain of 4% on more than twice average volume. Pfizer May Raise Bid for AstraZeneca to $106M The Rumor:
Pfizer PFE plans to raise its bid to around $106 million for AstraZeneca AZN, according to sources being reported by Bloomberg. The offer would value AstraZeneca at more than £50 per share. Sources say, the new offer could come as early as next week. AstraZeneca confirmed on April 28 that they had rejected Pfizer's $76.62 per share offer. AstraZeneca closed Thursday at $81.09, a gain of 2.5%. Pfizer closed at $31.15, a loss of $0.13. Microsoft Acquires Cloud-Computing Company GreenButton The Deal:
Microsoft MSFT announced on its blog Thursday the acquisition of cloud computing company Greenbutton. Microsoft says the existing GreenButton service will no longer be available to new customers and a new service integrated in Azure will be launched later in the year. Terms of the deal were not disclosed. Microsoft closed Thursday at $40.00, a loss of $0.40. Report Bayer Near Deal to Acquire Merck Consumer Unit The Rumor:
Bayer BAYRY is reportedly close to a deal to acquire the consumer products unit from Merck MRK, according to sources reported by Bloomberg. According to sources, the bid will be around $14 billion. Reckitt Benckiser RBGPF said on Wednesday it was no longer in talks with Merck regarding a deal. Merck closed Thursday at $59.62, a gain of almost 2%.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsRumorsM&AMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!